Update on the management of hyperuricemia and gout.


Journal Article (Review)

Gout is the most common inflammatory arthritis in the United States, with more than three million sufferers. Management of gout has changed relatively little in the past 50 years, despite the fact that many gout patients have contraindications to one or more currently available gout therapies. However, recent insights into gout pathophysiology suggest that time is ripe for a change. This article reviews recent updates in the management of gout, including new insights into dietary management that may permit better control of hyuperuricemia. Also reviewed are the biological and clinical data behind newly-developed drugs for gout that are likely to receive serious consideration for FDA approval, and clinical use, in the foreseeable future.

Full Text

Duke Authors

Cited Authors

  • Pillinger, MH; Keenan, RT

Published Date

  • 2008

Published In

Volume / Issue

  • 66 / 3

Start / End Page

  • 231 - 239

PubMed ID

  • 18937638

Pubmed Central ID

  • 18937638

International Standard Serial Number (ISSN)

  • 1936-9719


  • eng

Conference Location

  • United States